Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
H Y MeltzerM Maes

Abstract

It has been suggested that the clinical efficacy of chronic treatment with selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine and perhaps all antidepressants is due to their ability to enhance serotonergic activity. The effects of chronic treatment with fluoxetine or tricyclic antidepressants on the L-5-hydroxytryptophan (200 mg, L-5-HTP; PO)-induced increases in plasma cortisol and prolactin (PRL) concentrations were studied in patients with major depression or obsessive compulsive disorder (OCD). Administration of L-5-HTP increased plasma cortisol and PRL levels in medicated and unmedicated patients with major depression or OCD. The L-5-HTP-induced cortisol and PRL responses were significantly higher in fluoxetine-treated than in tricyclic-treated or unmedicated major depressed patients. The latter two groups did not differ significantly in their cortisol or PRL responses to L-5-HTP. The L-5-HTP-induced increases in cortisol and PRL in fluoxetine-treated patients with major depression or OCD were not significantly different. The results suggest that fluoxetine, but not tricyclic antidepressants, potentiates 5-HT receptor-mediated stimulation of cortisol and PRL secretion in humans, consistent with available ev...Continue Reading

Citations

Sep 30, 1999·Life Sciences·D K Raap, L D Van de Kar
Feb 12, 2002·Neuroscience and Biobehavioral Reviews·Tillmann H C KrügerMichael S Exton
Jan 14, 2000·Psychoneuroendocrinology·V HendrickS Korenman
May 3, 2006·Journal of Personality and Social Psychology·Sally I PowersAline Sayer
Sep 1, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Eduard Maron, Jakov Shlik
May 2, 2014·Journal of Clinical Psychopharmacology·Birmay Cam, Tunay Karldere
Mar 23, 2002·Journal of Clinical Psychopharmacology·Harm J GijsmanAdam F Cohen
Nov 6, 2012·Gynécologie, obstétrique & fertilité·S Alvarez, E Devouche
Jan 23, 2010·The Journal of Sexual Medicine·Margaret E WiermanJan L Shifren
Jan 21, 2006·The Journal of Sexual Medicine·Rossella NappiIrwin Goldstein
Feb 24, 2001·Mayo Clinic Proceedings·M C Peterson
Dec 4, 2010·Biological Psychiatry·Bernhard Luscher, Qiuying Shen
Sep 23, 2008·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·María Eugenia HernándezLenin Pavón
Mar 27, 2013·Basic & Clinical Pharmacology & Toxicology·Juliane C MüllerPaulo R Dalsenter
Sep 24, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Evelyn KiiveJaanus Harro
Dec 28, 2005·Psychoneuroendocrinology·Stephen L LoweRichard W Peck
Jul 19, 2005·Pharmacology & Therapeutics·Erick H TurnerAaron D Blackwell
Jun 29, 2010·Journal of Affective Disorders·Nadia IovienoDavid Mischoulon
Jan 2, 2015·Fertility and Sterility·Silvia Alvarez
Oct 25, 2016·Trends in Pharmacological Sciences·Jacob P R JacobsenMarc G Caron
Aug 2, 2013·Journal of Psychopharmacology·Abdulla A-B Badawy
Mar 14, 2019·Clinical Neuropharmacology·Nuran EkinciÖzalp Ekinci
May 30, 2017·Frontiers in Psychology·Kathleen A Moore, Jacqui Howell
Jan 1, 2008·International Journal of Tryptophan Research : IJTR·Eduard MaronDavid J Nutt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.